Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

146.00 -4.52 (-3.00%)
Streaming Delayed Price Updated: 3:54 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers. 
Via Benzinga
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
Oragenics announced its lead candidate, ONP-002, for treating concussion, which shows no cardiotoxicity in studies. Designed for nasal delivery to the brain, ONP-002 aims to address the significant... 
Via Benzinga
Critical Insights From Charles River Analyst Ratings: What You Need To Know
Via Benzinga
Demystifying Charles River: Insights From 4 Analyst Reviews
Via Benzinga
The Analyst Verdict: Charles River In The Eyes Of 4 Experts
Via Benzinga
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Wall Street Ends Wednesday In The Red As Risk Sentiment Remains Fragile: S&P 500 Movers At The Close
U.S. markets close lower on Wednesday after bounce back on Tuesday, with small caps hit hardest. Investors assess economic outlook and Fed rate cut. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast
Charles River Laboratories reported Q2 2024 revenue of $1.03 billion, a 3.2% decrease year-over-year, surpassing the $1.024 billion consensus. Adjusted EPS rose to $2.80 from $2.69. The company revised... 
Via Benzinga
Charles River Labs Plummets 17% On 'Bleaker' Expectations For 2024
Pharmaceutical demand hit the skids in the second quarter and isn't expected to improve this year. 
Via Investor's Business Daily
The Analyst Landscape: 7 Takes On Charles River
Via Benzinga
Charles River Laboratories Announces Second-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Apple To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Charles River to Perform Plasmid Manufacturing for AAVantgarde
From Charles River Laboratories International, Inc.
Via Business Wire
These Nike Analysts Are No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at William Blair and Jefferies Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
From Charles River Laboratories International, Inc.
Via Business Wire
CRL Stock Earnings: Charles River Beats EPS, Beats Revenue for Q1 2024
CRL stock results show that Charles River beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Charles River Laboratories Announces First-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
The 7 Best Growth Stocks to Buy in May 2024
Find real bargains in this marketplace with these seven best growth stocks to buy today for your portfolio. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.